

A cross sectional serologic and epidemiological study of dengue virus infection in north central area of Trinidad and Tobago.

ABSTRACT

Aims: This study was carried out to determine the observed serological and significant epidemiological risk factors for dengue fever infection in a cross-section of the population in Trinidad and Tobago.

Study design: This was a prospective cross sectional study.

Place and Duration of Study: The study was carried out in the department of Paraclinical Sciences of the University of the West Indies, St. Augustine Campus, Trinidad and Tobago, over a period of 10 months, October 2016 to July 2017.

Materials and Methods: Over 450 individuals from a cross section of the population residing in the northern part of Trinidad Island were surveyed. These included individuals suspected of having dengue fever that presented to the health care facilities with complaints of fever along with some other additional symptoms of viral illness. There was no age, gender or ethnic bias. Standardized questionnaire was used to obtain epidemiological data. Blood samples taken from consented participants were analyzed using rapid immune chromatographic tests (ICTs) – Panbio, SD Bioline and Enzyme Linked Immunosorbent Assays (ELISA). The samples were also tested for baseline blood parameters; platelets and haemoglobin. The epidemiological data was analyzed using SPSS version 21.

Results: Analysis of 380 individuals who fulfilled study criteria revealed that there were no demographic characteristics (age, gender, locality, etc.) that showed statistical significance with having a dengue infection. Retro-orbital pain, headaches and respiratory symptoms (e.g., cough, cold) showed differences that were significant with those having a dengue infection. No statistical significance was found in any comorbidity (diabetes, hypertension and asthma) factors considered and patients with dengue infections. Evaluation of platelet counts showed that only 5.4% samples had abnormal range and while four out of that five tested positive, this was not significant. Monitoring of platelet levels is still very important, but it showed that it is not an indicator of worsening dengue because 95.3% of the positive cases were within normal levels.

Conclusions: Except for nonspecific symptoms observed among patients suspected of dengue fever, there were no other significant factors that were exclusive in identifying dengue infection among the subjects studied. Platelet monitor cannot be used alone as a parameter to determine deteriorating dengue patients.

Keywords: Dengue fever, ELISA, Epidemiology, Serology, Panbio, Trinidad and Tobago.

1. INTRODUCTION

Dengue is now a global public health problem that is endemic in more than 100 countries with an estimated 50 – 100 million infections annually^{1, 2}. Dengue fever is an acute manifestation of an arthropod borne viral infection with dengue virus belonging to the *Flaviviridae* family and is transmitted by the bite of a female *Aedes aegypti* mosquito. Four serotypes of the virus are known to exist DEN-1-4³, and a recently documented fifth serotype appears to have emerged⁴. Classic dengue fever is usually self-limiting, especially in children. Dengue infection manifests in several severe forms, including dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS). Dengue haemorrhagic fever is associated with re-infection, characterized by the defects in homeostasis and plasma leakage into interstitial spaces associated with increased levels of vasoactive cytokines⁵. This leads to life threatening shock (DSS) in some cases.

The severe syndromes occur in patients with passively acquired or pre-existing, non-neutralizing, heterologous antibody caused by a previous infection with a different serotype of the virus⁶. The

27 antibodies from the previous infection bind to the new infecting serotype and facilitate viral entry via
28 Fc-receptor binding cells, so the number of antigen-presenting cells is increased at secondary
29 infection⁵. In 2016, there was a recorded 1,801 probable cases alone in Trinidad and Tobago out of
30 the total 9,993 probable cases in the non-Latin (English, French and Dutch) Caribbean⁷. This is a
31 significant decrease in the number of reported cases when compared to 2014; with 9,970 probable
32 cases. As was noted in a prospective sero-epidemiological study, many dengue infections do not
33 produce symptoms and the number of reported cases underestimates the actual prevalence of
34 dengue in the population^{8,9}.

35 The aim of this study was to serologically confirm the frequency of dengue virus infection and
36 determine epidemiological risk factors associated with dengue infections among patients suspected of
37 having dengue fever and attending health care facilities in the north central region of Trinidad and
38 Tobago.

39

40 2. MATERIAL AND METHODS

41

42 2.1 Study design, sites and population

43 This was an observational cross sectional study conducted during the period of October 2016 – July
44 2017, among patients with suspected dengue infection. The study was carried out at two health care
45 facilities of the North Central Regional Health Authority (NCRHA) in Trinidad of the twin Island,
46 Trinidad and Tobago with catchment areas as indicated in the figure below (Fig 1). This area has a
47 high population density in the country and most dengue cases in the past were localized to this region
48 [10], hence the choice as the study area.

49

50 This study was carried out among patients who presented to these health care facilities with
51 suspected dengue infection. The study enlisted voluntary participants who gave written consent.
52 Standardized data collection form was used to obtain epidemiological information from the
53 participants. All study participants were seen and physically examined by a medical personnel
54 involved in the study. Suspected dengue infection is characterized by fever along with the following
55 clinical features: anorexia, rash, aches and pains, vomiting and nausea, abdominal pains and warning
56 signs include positive tourniquet test, leukopenia, thrombocytopenia (platelet count $<150 \times 10^9/L$),
57 abdominal tenderness, clinical evidence of plasma leakage and/or increase in haematocrit¹¹.


58

59

60

61 **Figure 1. Geographical map of Trinidad and Tobago showing the locality of individuals**
62 **surveyed for dengue virus fever in Trinidad and Tobago, 2016 – 2017**

63



64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97

2.2 Inclusion criteria

All patients of all age groups, gender, ethnic groups, social and educational level who presented to these health facilities with suspected dengue infection symptoms as enumerated above and gave written consent or assent were included in the study. Any patient who did not meet the previously mentioned requirements for suspected dengue infection or did not give consent was excluded from the study.

2.3 Collection of Specimen

A questionnaire was used to obtain patient biodata or information and clinical history. This was administered by one of the trained investigators to avoid bias and misinterpretation or misrepresentation of the responses from the participants. About 10ml of blood (5ml each in red and purple top tubes) was obtained through venipuncture and transported to the Department of Paraclinical Sciences, The University of West Indies, St. Augustine Campus; and Pathology Laboratory at the Eric Williams Medical Sciences Complex for further analysis. The blood samples were allowed to clot at room temperature, centrifuged and separated as soon as possible. They were then stored at 2-8°C for a maximum of two days or stored frozen at -30°C until complete testing.

2.4 Laboratory Analysis - Complete Blood Count

All samples were subjected to a routine complete blood count as part of the routine services offered to the patients by the health care facilities including platelet counts for each patient.

2.5 Rapid Immuno-chromatographic tests (ICTs)

The samples collected in the red top tubes were subjected to serological analysis using enzyme linked immunosorbent assay - ELISA, (Dengue Virus IgM/IgG capture DxSelect ELISA, Focus Diagnostics, Cypress, PA, USA) for detection of human serum IgM and IgG antibodies in dengue virus (DV) infections. Rapid immune-chromatographic tests (ICT) kits were used for detection of IgM

98 and IgG antibodies, and non-structural protein 1 (NS1) antigen; of sera collected and the results were
99 recorded.

100 2.6 Quality Controls

102 Controls for both the IgM/IgG ELISA kits were provided as follows: detectable controls (human sera),
103 non-detectable controls (human sera) and cut-off calibrators (human sera). Samples that were
104 collected from asymptomatic and healthy individuals during the time of the study were used as
105 controls for both of the rapid ICT tests. Controls were run every time when procedures were carried
106 out.

107 2.7 Statistical Analysis

109 Microsoft Excel was used for data entry and data analysis was performed using Statistical Package
110 for the Social Sciences (SPSS) 23.0 software. Chi-square test and Fisher's exact test were used to
111 compare categorical variables. The Chi-square was chosen for determination of association between
112 a tested variable and a positive dengue result. If a relationship existed between any of the variables,
113 the Chi-square value (p value) would reflect the strength of the association. The Fisher's exact test is
114 used in place of the Chi-square to measure the same association for smaller sample sizes. In cases
115 where the frequency counts are fewer than five in a two by two table, the test statistics (p) used is the
116 Fisher's exact value. A probability value (p) of < 0.05 was considered statistically significant.

117 3. RESULTS AND DISCUSSION

119 Over 150 individuals were recruited for the study. Only 380 of these gave consent, completed the
120 questionnaire, got evaluated and gave blood samples and hence were included in the final analysis.
121 Patients included were noted to have come from different ethnic groups of people living in this part of
122 the country as depicted on Figure 1 above. As reported by these patients (Table 1), 38.7% were of
123 mixed ethnicity followed by patients of African descents or ethnicity, 36.6%. The East Indian and
124 Spanish descents groups completed the ethnicity analysis with 22.6% and 1.1 % respectively. Most of
125 the samples were obtained from females (61.3 %) and the median age of all analyzed individuals in
126 the study was 26 years (range, 3 years to 87 years) but the prevalent age group surveyed was
127 between 21 – 30 years (Figure 2). The median time between onset of illness and collection of
128 specimens was 3 days (range, 1 to 50 days).

130 The laboratory tests or characterization of the blood samples using the ELISA reference for dengue
131 IgM and IgG, initially classified the analysis as 92.5% positive for dengue and 7.5% non-dengue. Of
132 those that tested positive for dengue, females were in the majority (60.5%) and 32.6% of all positive
133 cases were between the ages of 21-30 years old. Based on the clinical history, presentation of the
134 fever, body aches and headache, the blood samples and the subjects were further defined or
135 classified as acute cases or phase (74.2 %), convalescent cases or phase (18.3 %); and based on
136 immune status, as primary 5.4 % or secondary, 87.1 %.

138 Demographics were the first parameters used to determine what would qualify as risk factors in
139 acquiring a dengue infection. Being of a particular ethnic group had no bearing or significance on
140 whether the patient tested dengue positive. The majority of the positives (35.5%) were found to be of
141 'mixed' descent, followed by African descent (34.4%). There was also no association between living in
142 a particular area and contracting dengue, although most recruits were from the Arima area (Figure 1
143 above) as there was a high percent that tested positive (47.3 %) there.
144 The statistical analysis in this study revealed that retro-orbital pain, respiratory symptoms (cold,
145 cough, runny/stuffy nose) and headache (Table 1) had significant association with samples that tested
146 positive for dengue ($p < 0.05$). More than half (53.3 %) of patients surveyed that tested positive for
147 dengue reported experiencing retro-orbital pain; 88.4 % of dengue- positive patients experienced
148 headaches while 80.2 % experienced respiratory symptoms.

149 Platelet levels of the patients were analyzed and categorized as abnormal ($\leq 150 \times 10^9/L$) and normal
150 ($\geq 150 \times 10^9/L$). The largest numbers of dengue positives were found in the age group 21-30, 27.9%
151 in the normal platelet range and 4.7% in the abnormal platelet range (Table 2), however, this
152 difference was not statistically significant ($p = 0.172$). The age group 11-20 (Table 2) showed the
153 second highest number of dengue positives with 18.6%. The mean age of those that tested positive
154 was 29 years old, while the mean platelet counts were 130,000 and 293,000 within the abnormal and
155 normal range, respectively. Except for the age groups 21 – 30 that recorded abnormal platelet counts,
156 all the other age groups had no abnormal platelet counts.

158


159 The objective of this study was to use serological analysis to confirm frequency of dengue virus
 160 infection and make association between epidemiological risk factors that may exist among the
 161 patients suspected of the infection in a cross section of individuals in Trinidad and Tobago. Results
 162 from studies such as this can assist physicians stop speculating when it comes to a diagnosis of
 163 dengue in our locality as far too many cases go unnoticed or recorded as acute viral illness (AVIs).
 164 While accurate laboratory diagnosis can be very helpful in confirming the disease, it will also provide
 165 key data on the epidemiology and health burden of dengue, which is very useful for accurate public
 166 health surveillance¹². In this study, similar number of individuals reported their ethnicity to be either of
 167 African descent or mixed race; and many of these tested positive for dengue virus infections. Also
 168 majority of the participants surveyed gave their location to be Arima area which was also noted to be
 169 a significant factor in this study. The high number of positive results in each of these categories
 170 appears to only reflect the majority within the sampled population.

171

172 Symptoms were statistically analyzed to determine their associations with a dengue virus infection
 173 although dengue infections may initially be asymptomatic in 50 – 90% of individuals¹³. The significant
 174 ones include retro-orbital pain (eye pain), headaches and respiratory symptoms which are similar to a
 175 previous report¹⁴. Eye pain is particularly common in dengue infection along with headaches but the
 176 degree to which they are experienced are not quantifiable and so they remain non-specific. Most
 177 patients who tested positive for dengue antibodies also complained of body pains but this was not
 178 found to be significant. Reporting of having a previous infection of either dengue, chikungunya or zika,
 179 also did not show any differences for those who tested positive. Among the several patients that had
 180 already suffered from a dengue infection, none of them showed signs or symptoms that were more
 181 severe than those who said they never were infected with dengue. As dengue is one of the most
 182 under reported tropical disease³, it is very possible that patients who claimed to have never had
 183 dengue may be unaware of the past diagnoses seeing that symptoms are non-specific and home
 184 remedies are administered by patients themselves until symptoms subside. This way, there is and can
 185 be no accurate monitoring of the actual disease or possible burden of infection.

186

187 **Figure 2. Age and gender distribution of 380 patients surveyed for dengue virus infections in**
 188 **Trinidad and Tobago, 2016 - 2017.**



189

190

191

192

193

194

195

196

197

198 **Table 1. Characteristic features of 380 patients surveyed for dengue virus infection in the north**
 199 **central regional health authority, Trinidad and Tobago, 2016 – 2017 (%).**

201	Characteristics	Negative	Positive	p value	Number
202	analyzed	28 (7.7)	352 (92.3)		
203	Demographics				
204	Male	8 (28.6)	139 (39.5)	0.702	
205	Female	20 (71.4)	213 (60.5)	0.702	
206	African descent	12 (42.9)	131 (37.2)	1.000	
207	East Indian descent	4 (14.3)	82 (23.3)	1.000	
208	Mixed	12 (42.9)	135 (38.4)	1.000	
209	Spanish	0	4 (1.2)	1.000	
210	Symptoms				
211	Rash	4 (14.3)	41 (11.6)	1.000	
212	Headache	16 (57.1)	311 (88.4)	0.054*	
213	Retro-orbital pain	0	188 (53.5)	0.012*	
214	Body pain	20 (71.4)	274 (77.9)	0.654	
215	Joint pain	4 (14.3)	176 (50)	0.115	
216	Diarrhoea	8 (28.6)	119 (33.7)	1.000	
217	Cough, cold,				
218	runny nose	8 (28.6)	282 (80.2)	0.007*	
219	Gum/Nose bleeds	0	33 (9.3)	1.000	
220	Previous infections				
221	None	28 (100)	254 (72.1)	0.184	
222	Dengue	0	65 (18.6)	0.600	
223	Chikungunya	0	29 (8.1)	1.000	
224	Zika	0	4 (1.2)	1.000	
225	Co-morbidities				
226	Hypertension	0	17 (4.7)	1.000	
227	Diabetes	0	8 (2.3)	1.000	
228	Diabetes + HTN	0	4 (1.2)	1.000	
229	Asthma	0	37 (10.5)	1.000	
230	Other – Arthritis,				
231	PCOS, etc.	4 (14.3)	29 (8.1)	0.479	
232	None	24 (85.7)	254 (72.1)	0.670	
233	Mosquito Conditions				
234	Many mosquitoes in the area	24 (85.7)	237 (67.4)	0.428	
235	Nets/Screens at home	0	61 (17.4)	0.593	
236	Blocked drains around house	0	70 (19.8)	0.342	
237	Get bitten often	20 (71.4)	193 (54.7)	0.459	
238	No mosquito problems	4 (14.3)	111 (31.4)	0.670	

236
 237 *p < 0.05 is considered statistically significant. p values were determined using Chi – square tests.
 238 Data are presented as n (%) or median (interquartile range); HTN – hypertension, PCOS – polycystic
 239 ovary syndrome

241
 242 **Table 2. Age distribution of enzyme linked immunosorbent assay (ELISA) and platelet count**
 243 **of patients tested for dengue virus infection in a cross section of Trinidadian patient, 2016-**
 244 **2017 (%).**

246	Age Groups	Negative ELISA		Positive ELISA	
247		Abnormal	Normal	Abnormal	Normal*
248					
249					
250	1 – 10	0(0)	16(4.3)	0(0)	45(11.8)
251	11 – 20	0(0)	8(2.1)	0(0)	65(17.2)
252	21 – 30	4(1.0)	0(0)	16(4.3)	98(25.8)
253	31 – 40	0(0)	0(0)	0(0)	38(9.7)
254	41 - 50	0(0)	0(0)	0(0)	33(8.6)
255	51 – 60	0(0)	0(0)	0(0)	41(10.8)
256	61 – 70	0(0)	0(0)	0(0)	4(1.1)
257	71 – 80	0(0)	0(0)	0(0)	8(2.2)

258	81+	0(.0)	0(.0)	0(.0)	4(1.1)
259	TOTAL	4(1.0)	24(6.4)	16(4.3)	336(88.3)

260

261 The Platelet counts were considered as normal ($\geq 150,000$) and abnormal ($\leq 150,000$)

262

263

264 Co-morbidities such as hypertension, diabetes mellitus and asthma are among the non-communicable illnesses that are most prevalent in Trinidad and Tobago¹⁵. If left unmanaged they can lead to high morbidity and mortality rates. Whether or not either of these had any effects on the prevalence of dengue infection was also investigated. Most of those that were found positive for dengue infection showed no significant associations with having any medical conditions (asthma, diabetes, hypertension), being on any particular medications or having received any vaccines in the last two months prior to being enrolled. However, a study in Asia, attempted to show the association of diabetes mellitus with DHF. The study found that female, Chinese, age group 30-49 years with pre-existing diabetes mellitus or diabetes with hypertension were risk factors of developing DHF during an epidemic while dengue serotype 2 was predominant¹⁶. Neither of these characteristics were found to show any significant differences in our current study despite age group (21-30 years), gender (more females than males) or ethnicity (more of mixed ethnic group descents) gave more numbers; and also the fact that 25.5% of the sampled population in this study suffered from comorbidities.

277

278 In our locality where we do not have problem of distinguishing dengue from malaria that produces low platelet counts¹⁷, hence platelet counts have been one of the most important factors in tracking the progress of dengue infection. Monitoring platelet levels however, should not be the sole criteria to presume dengue infection as many patients in this study tested dengue positive without abnormal platelet counts that is indicative of plasma leakage. In a study by Lovera et al, they investigated platelet count as a risk factor of shock. Using a cut-off of $< 100 \times 10^9/L$ they found that children who did not develop shock exhibited similar percentage level of thrombocytopenia compared to patients who eventually developed it (47 % vs 49 %). The results were similar when the comparison included patients only with platelet counts $< 50,000/mL$ (28 % vs 25.6 %)¹⁸. In this present study, the mean platelet count for positive samples in patients 1- 10 years of age was $295 \times 10^9/L$. Those with abnormal counts were only found in the 21- 30-year-old age group and 80% of them tested positive for dengue virus. This adds up to 4.3% of those who tested positive but was not of any significance. None of the patients had platelet levels that were $< 50 \times 10^9/L$.

291

292 The Pan American Health Organization (PAHO) has already issued a release of the number of reported cases of dengue and severe dengue in the Americas by country for epidemiological week 39 (updated October 13, 2017). After week 32 in Trinidad and Tobago the number of probable reported cases were 206, none of which were laboratory confirmed⁷. This may very well be an indication of how the health sector had prioritized dengue infection in this country. It is no longer important to identify or confirm a true case of dengue as long as we successfully manage its viral symptoms. It is of utmost importance that all probable cases not only be reported but confirmed, especially if headway is to be made on curbing infection and development/implementation of a vaccine. The WHO has stated their position on the newly developed vaccine (CYD-TDV) saying that countries should consider introduction of the dengue vaccine only in geographic settings where epidemiological data indicate a high burden of disease¹⁹. The vaccine, also known as Dengvaxia, is the attenuated (recombinant) tetravalent vaccine that was created to be administered by 3 injections of 0.5ml given at 6-month intervals. We cannot indicate high burden of disease if the epidemiological data being collected is recorded incorrectly or disregarded. Hence, all assumptions for diagnoses need to be confirmed and confirmed by the most accurate methods.

307

308 4. CONCLUSION

309

310 Despite the limitations of this study that include the small sample size and lack of use of molecular tests for confirmation of dengue virus, the study still detected positive cases of dengue virus infections in the country. Except for nonspecific symptoms observed among patients suspected of dengue fever, there were no other significant factors that were exclusive in identifying dengue infection among the subjects studied. Platelet monitor cannot be used alone as a parameter to determine deteriorating dengue patients.

316

317 **CONSENT**

318

319 Informed consent was also obtained from each of the patients, along with assent from children that
320 were included in the study. Patients under the age of 18 were considered as children.

321

322 **ETHICAL APPROVAL**


323

324 Ethics approval for this study was obtained from the Campus Ethics Committee of the University of
325 the West Indies St. Augustine Campus and the North Central Regional Health Authority (NCRHA)
326 Ethics Committees. The study was carried out in accordance with the ethical standards laid down in
327 the 1964 declaration of Helsinki.

328

329 **REFERENCES**

330

331 1. Guzman A, Isturiz RE. Update on the global spread of Dengue. *Int J Antimicrobial Agents* 2018; 
332 Suppl 1:S40-S42.

333 2. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL et al. The global distribution
334 and burden of dengue. *Nature* 2013; 496:504-7

335 3. Gubler DJ. Dengue and dengue hemorrhagic fever. *Lin Microbiol Rev* 1998; 62:480-496. 

336 4. Mustafa MS, Rasotgi V, Jain S, Gupta V. Discovery of fifth serotype of dengue virus (DENV-5): A
337 new public health dilemma in dengue control. *Med J Armed Forces India* 2015; 71(1), 67-70.
338 doi:10.1016/j.mjafi.2014.09.011

339 5. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S et al. Dengue
340 viremia titer, antibody response pattern, and virus serotype correlate with disease severity. *J Infect*
341 *Dis* 2000; 181(1), 2-9. doi:10.1086/315215

342 6. Brooks GF, Carroll KC, Butel JS, Morse SA. Jawetz, Melnick & Adelberg's Medical Microbiology
343 (26 ed.) 2013; New York McGraw Hill Lange

344 7. PAHO. (2017). Number of Reported Cases of Dengue and Severe Dengue (SD) in the Americas,
345 by Country. Figures for 2016 (to week noted by each country). *Epidemiological Week / EW* 52
346 (Updated February 6, 2017). Accessed online June 10, 2018 from

347 www.paho.org/hq/dmdocuments/2016/2016-cha-dengue-cases-jan-26-ew-52.pdf

348 8. Chadee DD, Shivnauth B, Rawlins SC, Chen AA. Climate, mosquito indices and the epidemiology
349 of dengue fever in Trinidad (2002–2004). *Annals of Tropical Medicine & Parasitology* 2007; 101(1),
350 69-77. doi:10.1179/136485907X157059

351 9. Campbell CA, George A, Salas RA, Williams SA, Doon R, Chadee DD. Seroprevalence of dengue
352 in Trinidad using rapid test kits: a cord blood survey. *Acta Trop* 2007; 101(2), 153-158.
353 doi:10.1016/j.actatropica.2006.11.009

354 10. Chadee DD, Williams FL, Kitron UD. Impact of vector control on a dengue fever outbreak in
355 Trinidad, West Indies, in 1998. *Trop Med Int Health* 2005; 10(8), 748-754. doi:10.1111/j.1365-
356 3156.2005.01449.

357 11. WHO. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control: New Edition 2009;
358 World Health Organization. Accessed online June 10, 2018 from

359 www.who.int/rpc/guidelines/9789241547871/en

360 12. Parkash O, Shueb RH. Diagnosis of Dengue Infection Using Conventional and Biosensor Based
361 Techniques. *Viruses* 2015; 7(10), 5410-5427. doi:10.3390/v7102877

362 13. Kyle JL, Harris E. Global spread and persistence of dengue. *Anual Rev Microbiol* 2008; 62:71-92.

363 14. Gregory J, Santiago LM, Arguello DF, Hunsperger E, Tomashek KM. Clinical and laboratory
364 features that differentiate dengue from other febrile illness in an endemic area – Peurto Rico, 2007 –
365 2008. *Am J Trop Med Hyg* 2010; 82:922-929

366 15. WHO. Non communicable Diseases (NCD) Country Profiles, 2014: Trinidad and Tobago.
367 Accessed online June 10, 2018 from www.who.int/nmh/publications/ncd-profiles-2014/en

368 16. Pang J, Salim A, Lee VJ, Hibberd ML, Chia KS, Leo YS, Lye DC. Diabetes with hypertension as
369 risk factors for adult dengue hemorrhagic fever in a predominantly dengue serotype 2 epidemic: a
370 case control study. *PLoS Negl Trop Dis* 2012; 6(5), e1641. doi:10.1371/journal.pntd.0001641

371 17. Chadwick D, Arch B, Wilder-Smith A, Panton N. Distinguishing dengue fever from other infections
372 on the basis of simple clinical and laboratory features: application of logistic regression analysis. *J*
373 *Clin Virology* 2006; 35:147-153

374 18. Lovera D, Martinez de Cuellar C, Araya S, Amarilla S, Gonzalez N, Aguiar C, Arbo A. Clinical
375 Characteristics and Risk Factors of Dengue Shock Syndrome in Children. *Pediatr Infect Dis J* 2016;
376 35(12), 1294-1299. doi:10.1097/INF.0000000000001308

377 19. WHO. Dengue vaccine: WHO position paper Weekly Epidemiological Report 2016; 30(91), 349-
378 364.